Articles tagged with Cell Transplantation
A woman with HIV has achieved 14 months of undetectable HIV levels following a cord blood stem cell transplant to treat acute myeloid leukemia. The study suggests that CCR5Δ32/Δ32 cord stem cell transplantation may be an effective method for achieving HIV remission and cure in individuals requiring such transplants.
Researchers have developed a personalized dosing regime for anti-thymocyte globulin (ATG) to improve the success of stem cell transplants in children with leukemia. The new approach led to better immune recovery and higher survival rates compared to standard treatment.
A study published in Leukemia found that cord blood transplantation (CBT) was more effective than matched related donor transplantation (MRDT) for patients with refractory and relapsed acute myeloid leukemia (R/R AML). The study compared the survival rates of 1,738 CBT-treated patients with those of 713 MRDT-treated patients, revealing...
A clinical trial will harness synthetic chimeric antigen receptor (CAR) T cells to deplete immune B cells and plasma cells producing donor-specific antibodies, aiming to achieve a compatible kidney match for patients with pre-existing antibodies. The NIH-funded study, led by Penn Medicine, intends to begin enrolling patients in 2022.
Researchers at UC Davis Health developed a new treatment that simultaneously blocks IL-6 and TNF cytokines, providing superior protection against acute graft-versus-host-disease severity and mortality. The dual-cytokine blockade approach did not impair beneficial graft-versus-tumor effects.
A new gene and stem-cell therapy has been proven to be effective in treating Epidermolysis Bullosa (EB), a genetic skin disorder, without any side effects. The treatment, which involves transplanting genetically modified skin cells, has resulted in stable results after five years, with the patient now 13 years old.
A simple change in the way donor cells are processed can maximize a single cell's production of extracellular vesicles, which are small nanoparticles naturally secreted by cells. The finding offers new avenues for research around cellular therapies, where transplanted cells are used to help the body heal or work better.
Scientists at Kobe University have successfully generated testosterone-producing Leydig cells from human iPS cells, a significant step towards developing a regenerative medicine treatment for late-onset hypogonadism. The induced cells expressed genes specific to Leydig cells and produced functional testosterone.
A new study by USC researchers uses a genetic technology to analyze gene expression signatures of individual cancer cells from patients with leukemia. The findings show that cancer cells with distinct gene expression profiles tend to grow in different organs, while those with specific genes are more resistant to chemotherapy.
Researchers have developed a new method of stem cell transplantation that does not require chemotherapy or radiation. The approach uses immunotherapeutic drugs to eliminate cancer cells and prevent immune rejection. This technique has the potential to be curative for blood cancers and treat other diseases like sickle cell anemia.
Researchers report that 90% of patients who received gene therapy between 2009 and 2012 remain disease-free, with significant immune system differences observed among those treated. The therapy is most effective in younger children, but further work is needed to achieve high levels of gene correction in all patients.
A new pouch device has been developed to protect transplanted human liver cells from immune systems for up to six months, producing crucial biomolecules. This breakthrough offers a potential path toward treating human diseases without needing to suppress the patient's immune system.
Researchers have discovered the molecular mechanisms behind stem cell rolling in blood vessels, a complex process that slows down cells using long tethers. The findings offer new insights into improving stem cell transplantations and developing treatments for metastasizing cancers.
Researchers investigated antibody response to Pfizer-BioNTech vaccine in 117 allogeneic hematopoietic stem cell transplant recipients. The study aimed to assess vaccine safety and immune response in this population. Key findings were not reported in the article.
Researchers found that hematopoietic cell transplantation (HCT) normalizes the gut microbiota of patients with IBD associated with XIAP deficiency. The study revealed that HCT decreases gut inflammation and restores diversity in gut microbiota, improving symptoms and quality of life for affected individuals.
Scientists discovered beige fat cells mediate subcutaneous fat's brain protection and provide anti-inflammatory effects. Beige fat transplantation restored cognitive function in obese mice with dementia-like behavior.
Scientists at UCSF have shown that gene-edited cellular therapeutics can effectively treat major diseases such as peripheral artery disease, chronic obstructive pulmonary disease, and heart failure. The study used specially engineered induced pluripotent stem cells called HIP cells to evade the immune system.
A combination of ponatinib and blinatumomab achieves 100% complete response rate and 85% complete molecular remission in newly diagnosed patients, reducing the risk of treatment-related complications. The treatment is safe and well-tolerated, with no additional toxicity observed when used together.
Researchers have made new discoveries about fetal liver cells that could help make liver cell transplants more effective. Fetal liver cells can multiply and maintain function for long periods when used in transplants, but adult liver cells do not share this ability.
Researchers are developing new conditioning therapies with fewer side effects, targeting specific proteins on hematopoietic stem cells to make room for healthy ones. This could lead to more patients being able to safely undergo stem cell treatments, reducing complications and improving outcomes.
A new study finds that stem cell transplants after CAR T-cell therapy reduce relapse rates in childhood cancer patients by less than 10% two years later. The research suggests long-term benefits for young patients who receive the treatment, with most experiencing complete remission.
Non-circulating memory T cells play a crucial role in chronic transplant rejection by providing local protection against re-infection and causing prolonged immune responses. Targeting these cells could improve clinical transplant outcomes while preserving the immune system's ability to fight off infections.
A new analysis indicates that patients with kidney failure associated with sickle cell disease benefit from kidney transplantation to a similar extent as patients with kidney failure from other causes. Despite this, the sickle cell population is less likely to receive transplants.
A study found that intense immunosuppression followed by hematopoietic stem cell transplants can prevent disability associated with multiple sclerosis (MS) from getting worse in up to 71% of people with relapsing-remitting MS for up to 10 years. In some cases, disability improved over time.
A groundbreaking study by Liu et al successfully transplanted adult human eye stem cells into monkeys' eyes, restoring normal vision and supporting photoreceptor function. The retinal pigment epithelium-derived cells showed no serious side effects and integrated stably for at least three months.
Researchers found that removing the internal limiting membrane can help transplanted retinal cells integrate into the retina, improving vision loss caused by glaucoma and other diseases. The study aims to develop new ways to repair or replace lost optic neurons by growing new cells.
A mathematical model developed by researchers predicts that autologous gene-edited stem cell transplants could achieve viral control after antiretroviral therapy withdrawal. The conditions required for this include a sufficient dose of edited stem cells and allowing them to repopulate the blood before ART is stopped.
New research suggests that testing for tumor DNA in DLBCL patients' stem cells or blood can help predict relapse risk. Patients with positive results may benefit from alternative treatments like CAR T cell therapy and prompt interventions to prevent relapse.
A new clinical trial has found that donor stem cell transplantation nearly doubles the survival rate of older patients with higher-risk myelodysplastic syndrome (MDS), aged 50-75. The study suggests that transplant should be considered for all eligible patients, ideally referred early to increase chances of finding a suitable donor.
Researchers identified two cell signals that can guide stem cells to repair eye damage, increasing their survival and function after transplantation. The study's findings offer a promising approach to restoring eyesight by modifying stem cells with enhanced chemokine receptors.
A recent study by MedUni Vienna dermatologists has discovered that skin-resident and inactive T cells survive chemotherapy and radiotherapy intact and go on to cause inflammation after a stem cell transplant. In some cases, these tissue-resident T cells even prove beneficial to the recipient by assuming their role in immune defense.
Researchers describe a rare case of frosted branch angiitis, a unique presentation of florid retinal vasculitis, in a woman treated for leukemia-lymphoma with allogeneic human stem cell transplant. The condition led to immune activation and required corticosteroids to suppress inflammation.
Scientists have discovered that baking soda can reprogram T cells to resist cancer cells' immune-suppressive effects. The treatment has reversed the suppressive effects on T cells in 10 transplant recipients with relapsed AML.
Researchers at the University of Wisconsin-Madison have developed a stem cell treatment that repairs Parkinson's-damaged brain circuits in mice. The treatment involves coaxing human embryonic stem cells to differentiate into dopamine-producing neurons, which then integrate into the correct regions of the brain and restore motor functions.
Researchers developed an 'cell-less' therapy that accelerates recovery from heart attack in pigs by injecting tiny membrane-bound sacs containing proteins and DNA into the heart. This approach avoids safety concerns associated with whole-cell transplants, which often fail to engraft and can cause severe health issues.
Researchers at Keck School of Medicine of USC have received a five-year, $14.6 million grant to advance gene therapy for HIV control without daily medicines. The approach is inspired by three cases of HIV cure and aims to prepare patients for stem cell transplants with little toxicity.
Scientists at Joslin Diabetes Center have developed a novel cell-based therapy using 'HUMBLE' cells, genetically modified human white fat cells that mimic heat-generating brown fat cells. Transplanted into mice with type 2 diabetes, these cells improved insulin sensitivity and glucose clearance, reducing weight gain and related chronic...
Researchers studied iPS cell-derived heart muscle cells after transplantation to understand the phenomenon of irregular heartbeats. They found that the activity of working-type cells increases significantly, while nodal-like cells decrease in proportion, leading to a reduction in arrhythmia.
Testicular tissue transplantation combined with retinoic acid administration successfully produces healthy offspring in mice, offering a potential method for preserving/recovering male fertility. The researchers' findings suggest that this approach may be effective in humans without adverse effects on pregnant mothers.
Sylvester researchers have identified a potential protein target, STING, that may help mitigate graft versus host disease in stem cell transplants. In preclinical models, inhibiting the STING pathway reduced symptoms of GVHD.
A new study aims to enhance cord blood transplant success rates using a small molecule cell adhesion activator. The treatment has shown promise in preclinical studies and may provide a safer alternative to current methods.
A new cell therapy approach has been shown to reduce the need for immunosuppression in kidney transplant recipients, thereby minimizing the risk of side effects. The study found that regulatory cells were just as safe as standard treatment and did not result in higher rejection rates.
A new animal study demonstrates that transplanted human glial cells can repair damage and restore function in models of multiple sclerosis. The findings have significant therapeutic implications and represent a proof-of-concept for clinical trials.
A new method uses CAR-T therapy to eliminate leukemia stem cells and blood stem cells selectively, sparing mature blood cells and other tissues. The treatment is achieved through genetic modification of immune cells, which then target and destroy only the leukemic stem cells.
Using reprogrammed human skin cells, researchers successfully restored mobility and sensation in stroke-afflicted rats by transplanting them into their brains. The study showed that the transplanted cells formed connections correctly, repairing damaged nerve circuits.
Grafted neurons derived from human induced pluripotent stem cells functionally integrated into brain circuitry and restored motor function in stroke-injured rats. The study suggests that stem cell-derived neurons can replace dead cells to restore motor function.
Researchers at MIT have developed a way to encapsulate therapeutic cells in a flexible protective device that prevents immune rejection while allowing oxygen and nutrients to reach the cells. This technology could lead to long-term treatment of chronic diseases such as diabetes.
A newly discovered blood marker has been linked to a patient's subsequent risk of kidney transplant failure in a study of 284 kidney transplant recipients. The composition of immune cells called CD8+ memory T cells 1 year after kidney transplantation was found to be a critical factor in predicting organ rejection.
A study of a second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy. The patient had a healthy CD4 cell count, suggesting they have recovered well from the transplant.
A phase 2 randomized trial study found that patients who received the Triplex vaccine had 50% fewer CMV complications and developed immunity against the virus. The vaccine showed promise as a potential therapy for transplant recipients with weakened immune systems.
Researchers found that iPSC-derived thymic epithelium cells can regulate immune response to skin grafts, extending their survival. The introduction of Foxn1 gene helps efficient differentiation of such cells.
A new study in 50 patients found that persistent mixed chimerism can reduce the reliance on immunosuppressive drugs after a kidney transplant. The treatment achieved immune tolerance and reduced rejection episodes, allowing some patients to survive with their donated kidneys for over eight years.
A pilot study of 25 donor-recipient pairs reveals young stem cell donors have previously undetected and potentially disease-causing mutations in their blood stem cells. These mutations, linked to post-transplant complications, are more prevalent in young donors than thought.
A recent study found that oral infections are not linked to increased risk of death or serious infection after stem cell transplantation. The researchers suggest that conservative dental treatment may be sufficient for patients with asymptomatic dental infections, and radical treatment is only necessary in specific cases.
A new analysis reveals that donor stem cell transplantation following PD-1 treatment is generally safe and produces good outcomes for patients with Hodgkin lymphoma. Post-transplant treatment with cyclophosphamide may also lead to improved results, reducing rates of acute GVHD and relapse.
Researchers identified genetic mutations that predict patient outcomes after a stem cell transplant for acute myeloid leukemia (AML) in patients over age 60. Patients with specific gene mutations were classified into low, high, or intermediate-risk groups, enabling personalized treatment approaches.
A study by Dana-Farber researchers suggests that adding venetoclax to a reduced-intensity drug regimen prior to stem cell transplant can increase the chances of transplant success. The treatment has been found to be safe and does not impair donor cells' ability to engraft in recipients.
Researchers have found that abatacept significantly reduces severe acute GvHD in high-risk patients, with a one-year survival rate of 85%. The drug suppresses effector T cells, which can also trigger infections or relapse in cancer patients.
Researchers have successfully transplanted human neurons into a mouse brain, allowing them to study human neural circuit formation and potential diseases. The transplanted cells followed a months-long period of maturation typical for human neurons and were able to function in the mouse neural circuits.
Researchers at the University of California, Irvine developed a cell therapy that transplants inhibitory neurons to improve memory precision after traumatic brain injury. The treatment prevented seizures in mice with traumatic brain injuries, showing promising results for potential human treatment.